Cardiovascular Diagnostics files for monitoring tests:
This article was originally published in Clinica
Executive Summary
Cardiovascular Diagnostics is seeking US clearance for two tests to monitor the effects of anti-clotting drugs. The Ecarin clotting time test is designed to monitor the effects of the thrombin inhibitor PEG-Hirudin, made by German pharmaceutical company Knoll. The low range heparin management test measures heparin levels in the ranges needed during cardiac catheterisation. Both tests are based on the company's Thrombolytic Assessment System, a dry chemistry technology platform from which it has developed a range of therapeutic diagnostics for angina, heart attack, stroke and deep vein thrombosis and pulmonary and arterial emboli.